IART vs. ICUI, NARI, MDXG, INSP, MMSI, GMED, MASI, ITGR, ATEC, and ATRC
Should you be buying Integra LifeSciences stock or one of its competitors? The main competitors of Integra LifeSciences include ICU Medical (ICUI), Inari Medical (NARI), MiMedx Group (MDXG), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Globus Medical (GMED), Masimo (MASI), Integer (ITGR), Alphatec (ATEC), and AtriCure (ATRC). These companies are all part of the "medical" sector.
ICU Medical (NASDAQ:ICUI) and Integra LifeSciences (NASDAQ:IART) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
96.1% of ICU Medical shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 6.7% of ICU Medical shares are owned by company insiders. Comparatively, 3.1% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Integra LifeSciences received 53 more outperform votes than ICU Medical when rated by MarketBeat users. However, 64.48% of users gave ICU Medical an outperform vote while only 57.82% of users gave Integra LifeSciences an outperform vote.
In the previous week, ICU Medical had 4 more articles in the media than Integra LifeSciences. MarketBeat recorded 7 mentions for ICU Medical and 3 mentions for Integra LifeSciences. ICU Medical's average media sentiment score of 1.19 beat Integra LifeSciences' score of 0.96 indicating that Integra LifeSciences is being referred to more favorably in the news media.
ICU Medical presently has a consensus price target of $123.00, suggesting a potential upside of 15.67%. Integra LifeSciences has a consensus price target of $35.00, suggesting a potential upside of 13.27%. Given Integra LifeSciences' stronger consensus rating and higher possible upside, research analysts plainly believe ICU Medical is more favorable than Integra LifeSciences.
ICU Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
Integra LifeSciences has a net margin of 2.63% compared to Integra LifeSciences' net margin of -2.63%. ICU Medical's return on equity of 14.27% beat Integra LifeSciences' return on equity.
Integra LifeSciences has lower revenue, but higher earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Integra LifeSciences beats ICU Medical on 11 of the 18 factors compared between the two stocks.
Get Integra LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IART and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integra LifeSciences Competitors List
Related Companies and Tools
